📄 medicine

Unlocking Dormant Ovarian Function: A Phase I Clinical Trial of Regenerative Stem Cell Therapy Combined with in Vitro Ovarian Activation

This Phase I clinical trial demonstrates that combining in vitro ovarian activation with Wharton's jelly-derived mesenchymal stem cell injections is a safe and promising regenerative strategy for restoring ovarian function and menstrual cycles in women with premature ovarian failure, warranting further investigation in larger controlled studies.

Original authors: Marzieh Mehrafza, Elham Vojoudi, Azadeh Raoufi, Zahra Barabadi, Zeinab Zarei-Behjani, Saman Maroufizadeh, Massoud Vosough, Naser Amini, Tahereh Zare Yousefi

Published 2026-07-14

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Marzieh Mehrafza, Elham Vojoudi, Azadeh Raoufi, Zahra Barabadi, Zeinab Zarei-Behjani, Saman Maroufizadeh, Massoud Vosough, Naser Amini, Tahereh Zare Yousefi

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your ovaries as a vast, quiet library where thousands of tiny, sleeping books (eggs) are waiting to be read. In a condition called Premature Ovarian Failure (POF), the lights go out, the librarians stop working, and the books get buried under a thick layer of dust and sticky glue (fibrosis). For years, the only way to get a story out of this library was to borrow books from someone else (donor eggs), which is a heavy emotional burden for many families.

But what if we could wake up the sleeping books and clean the glue ourselves? That's the big question a team of researchers in Iran asked in a new study. They didn't just try one trick; they tried a "double-tap" strategy to see if it was safe and if it might work.

The Double-Whammy Plan
Think of the treatment as a two-step rescue mission for the library:

The "Shake-Up" (In Vitro Ovarian Activation): First, the surgeons took a tiny piece of the ovarian tissue and chopped it into small bits. Imagine taking a tangled ball of yarn and snipping it into smaller pieces. This mechanical "chopping" is like breaking a dam; it signals the dormant eggs to wake up and start growing. This is called in vitro ovarian activation (IVA).
The "Repair Crew" (Stem Cell Injection): Just waking the eggs up isn't enough if the library is still covered in sticky glue. So, the team injected a special team of "repair workers" called Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs). These cells come from the umbilical cord (the lifeline between a baby and mom) and are famous for being gentle, non-rejectable, and great at fixing broken tissues. They act like a cleanup crew, dissolving the sticky glue (fibrosis) and bringing fresh supplies to help the eggs survive.

The Experiment
The researchers tested this combo on 10 women aged 18 to 40 who had POF. They performed the surgery on one ovary (the "treated" side) and left the other alone to act as a control. They then watched what happened for 12 months.

What Actually Happened?
Here is the good news, but with a very important "maybe" attached:

Safety First: The most important finding is that the treatment was safe. Over the entire year, no one got sick from the stem cells, had a bad reaction, or developed tumors. The "repair crew" didn't cause any trouble.
The Library Woke Up: Out of the 8 women who finished the full year of follow-up, 6 started having their monthly periods again. That's a big deal! Before the treatment, they hadn't had a period for at least 6 months.
The "Glue" Got Thinner: The women reported feeling better. Their "hot flashes" and sleep trouble (menopause symptoms) got significantly better. Also, the lining of their uterus (the "floor" of the library) got thicker, which is a sign that the body was starting to produce hormones again.
The Hormone Numbers: The researchers checked the blood levels of the "boss hormones" that tell the ovaries what to do.
- FSH (Follicle-Stimulating Hormone): This number, which is usually sky-high in POF, dropped significantly in the first 3 months for those who got their periods back. However, by 6 months, the drop wasn't statistically "proven" for the whole group because one person's numbers went back up, showing that every body is different.
- LH (Luteinizing Hormone): This number went down significantly and stayed down for the whole 6 months, suggesting the body's internal clock was resetting.
- Estradiol and AMH: These are the "fuel" and "inventory count" numbers. The study did not find a statistically significant change in these levels. While some women saw a tiny bump, the paper is careful to say this wasn't a guaranteed result for everyone.

What the Paper Says It Is NOT
It is crucial to understand what this study did not prove.

It is not a cure-all: The paper explicitly states that this was a Phase I trial. This means the main goal was to check if the treatment was safe, not to prove it works perfectly for everyone.
It is not a guarantee of pregnancy: While 4 of the women went on to try IVF (a fertility treatment) after the surgery, the study did not measure or report pregnancy rates or live births. The researchers are not saying this treatment will definitely lead to a baby; they are saying it might help the ovaries start working again.
It is not a magic wand for everyone: The results varied. The paper notes that the lack of a huge change in some hormone levels might be because the group was small (only 10 people) or because the women had different types of POF.

The Bottom Line
Think of this study as a successful test drive of a new car engine. The engine didn't explode (it was safe), and the car started moving (periods returned for most). But the researchers haven't driven it across the country yet to see how far it can go or if it will win a race.

The paper suggests that combining the "chopping" (IVA) with the "repair crew" (stem cells) is a promising way to unlock dormant ovaries. It suggests that for some women, this could mean waking up their own fertility potential and feeling better. However, the authors are very clear: we need bigger studies with more people to know for sure if this is a reliable way to treat POF. For now, it's a hopeful spark, not a solved problem.

Technical Summary: Unlocking Dormant Ovarian Function via Combined WJ-MSC Therapy and In Vitro Ovarian Activation

Problem Statement
Premature Ovarian Failure (POF), or Primary Ovarian Insufficiency (POI), is a condition affecting women under 40, characterized by amenorrhea, elevated gonadotropins (FSH), low estrogen, and a depleted primordial follicle pool. Current standard treatments, such as Hormone Replacement Therapy (HRT) and Assisted Reproductive Technologies (ART) using donor eggs, offer limited efficacy in restoring autologous ovarian function. These approaches often fail to address the underlying pathology, which includes ovarian fibrosis and the presence of dormant follicles that are unresponsive to conventional hormonal stimulation. Furthermore, reliance on egg donation presents significant psychological burdens regarding genetic connection and ethical concerns regarding donor well-being. There is an unmet clinical need for therapies that can reactivate dormant follicles and repair the fibrotic ovarian microenvironment to restore natural fertility potential.

Methodology
This study was a Phase I, uncontrolled clinical trial designed to evaluate the safety and preliminary efficacy of a novel combination therapy: in vitro Ovarian Activation (IVA) combined with the intraovarian injection of Wharton's Jelly-derived Mesenchymal Stem Cells (WJ-MSCs).

Study Population: Ten women aged 18–40 diagnosed with POF were enrolled. Inclusion criteria included a 46,XX karyotype, secondary amenorrhea for at least six months, serum AMH <0.42 ng/mL, and FSH >25 IU/L on two occasions. Two participants dropped out, leaving eight for the final analysis.
Intervention Protocol:
1. WJ-MSC Preparation: Mesenchymal stem cells were isolated from umbilical cords of healthy donors, expanded under Good Manufacturing Practice (GMP) conditions, and characterized for positive markers (CD105, CD73, CD90) and negative hematopoietic markers (CD45, CD34).
2. Surgical Procedure: Under laparoscopy, a 1×1 cm piece of the left ovarian cortex was harvested. The tissue was fragmented into 1×1 mm pieces to mechanically disrupt the Hippo signaling pathway (a key mechanism in IVA).
3. Transplantation: The fragmented ovarian tissue was re-implanted into the left ovarian cortex. Simultaneously, $10 \times 10^6$ WJ-MSCs were injected locally into the same ovary. The right ovary served as a sham control (no intervention) for safety comparison.
Follow-up: Participants were monitored for 12 months. Primary outcomes focused on safety (adverse events). Secondary outcomes included the resumption of menstruation, serum levels of AMH, FSH, LH, and Estradiol (E2), endometrial thickness, and the severity of menopausal symptoms.

Key Contributions
The paper introduces a synergistic therapeutic strategy that addresses two distinct pathological barriers in POF:

Follicular Reactivation: Utilizing IVA (mechanical fragmentation) to disrupt the Hippo pathway and activate the PI3K/AKT signaling cascade, thereby stimulating dormant primordial follicles.
Microenvironment Repair: Utilizing WJ-MSCs to mitigate ovarian fibrosis, reduce inflammation, and support tissue regeneration through paracrine mechanisms (secretion of growth factors and cytokines) rather than direct differentiation.
The study provides the first clinical evidence of combining these two modalities in a single surgical intervention for human POF patients.

Results

Safety: The intervention demonstrated an excellent safety profile. No treatment-related adverse events, graft-versus-host disease, tumorigenesis, or severe immune reactions were observed during the 12-month follow-up.
Menstrual Recovery: Among the eight patients who completed the study, six (75%) regained regular menstrual cycles, a statistically significant improvement from baseline ( $P = 0.002$ ). This recovery was sustained throughout the 12-month period.
Hormonal Changes:
- FSH: A significant decrease in FSH levels was observed at the 3-month mark ( $P = 0.024$ ), though this significance was not maintained at 6 months due to inter-individual variability.
- LH: Serum LH levels showed a significant decline from baseline that persisted through the 6-month follow-up ( $P = 0.013$ ).
- AMH and E2: Changes in Anti-Müllerian Hormone (AMH) and Estradiol (E2) levels were not statistically significant across the group, though a modest increase in AMH was noted in a subset of patients.
Clinical Symptoms and Anatomy: Six patients reported a significant reduction in the severity of menopausal symptoms (e.g., hot flashes, insomnia) ( $P = 0.031$ ). Endometrial thickness increased significantly at 3 and 6 months ( $P = 0.007$ ), indicating improved endometrial responsiveness.
Reproductive Outcomes: Four patients subsequently underwent IVF cycles, but pregnancy and live birth rates were not primary endpoints and were not reported in this study.

Significance and Claims
The authors claim that this Phase I trial establishes the safety and feasibility of combining WJ-MSC transplantation with IVA for treating POF. The study posits that while IVA alone may struggle to overcome the fibrotic ovarian microenvironment, and stem cell therapy alone may lack sufficient stimulation for dormant follicles, their combination offers a synergistic approach.

The paper modestly concludes that the observed restoration of menstrual function and improvement in menopausal symptoms suggest a partial functional recovery of ovarian activity. The authors emphasize that while the safety profile is robust, the efficacy data (particularly regarding hormonal markers like AMH and E2) requires validation. They explicitly state that larger, randomized controlled trials with longer follow-up periods are necessary to confirm the therapeutic efficacy, optimize cell dosing, and determine the potential for live births. The study does not claim to have "cured" POF but rather presents a promising regenerative avenue that warrants further investigation.

Technical Summary: Unlocking Dormant Ovarian Function via Combined WJ-MSC Therapy and In Vitro Ovarian Activation

More like this